Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock: Insider Michael Exton Buys 30,064 Shares

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) CEO Michael Exton acquired 30,064 shares of the stock in a transaction that occurred on Friday, November 6th. The shares were bought at an average price of $1.66 per share, with a total value of $49,906.24. Following the completion of the transaction, the chief executive officer owned 328,496 shares in the company, valued at $545,303.36. This represents a 10.07% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Lexicon Pharmaceuticals Trading Up 2.2%

Shares of NASDAQ:LXRX opened at $1.86 on Wednesday. Lexicon Pharmaceuticals, Inc. has a one year low of $1.10 and a one year high of $2.68. The company has a debt-to-equity ratio of 0.32, a current ratio of 10.62 and a quick ratio of 10.56. The firm has a 50 day simple moving average of $1.80 and a 200 day simple moving average of $1.89.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its earnings results on Thursday, November 5th. The biopharmaceutical company reported ($0.03) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.03. The firm had revenue of $11.25 million for the quarter, compared to analysts’ expectations of $4.14 million. Lexicon Pharmaceuticals had a negative net margin of 161.80% and a negative return on equity of 35.76%. As a group, research analysts anticipate that Lexicon Pharmaceuticals, Inc. will post -0.16 EPS for the current fiscal year.

Institutional Trading of Lexicon Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in LXRX. Pictet Asset Management Holding SA acquired a new stake in Lexicon Pharmaceuticals in the 3rd quarter valued at $41,000. Profund Advisors LLC increased its stake in Lexicon Pharmaceuticals by 600.8% during the 3rd quarter. Profund Advisors LLC now owns 340,479 shares of the biopharmaceutical company’s stock valued at $638,000 after purchasing an additional 291,893 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in Lexicon Pharmaceuticals during the third quarter worth $66,000. WINTON GROUP Ltd raised its holdings in Lexicon Pharmaceuticals by 69.4% during the second quarter. WINTON GROUP Ltd now owns 43,200 shares of the biopharmaceutical company’s stock worth $104,000 after buying an additional 17,700 shares during the last quarter. Finally, Squarepoint Ops LLC acquired a new position in Lexicon Pharmaceuticals during the second quarter worth $28,000. 74.70% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

LXRX has been the subject of several recent research reports. Citigroup upped their price objective on Lexicon Pharmaceuticals from $3.10 to $3.40 and gave the company a “buy” rating in a research note on Monday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Lexicon Pharmaceuticals in a research report on Wednesday, October 21st. Wall Street Zen raised Lexicon Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Sunday. Cantor Fitzgerald began coverage on shares of Lexicon Pharmaceuticals in a research report on Monday, September 28th. They set an “overweight” rating and a $8.00 target price for the company. Finally, Zacks Research lowered shares of Lexicon Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 3rd. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Lexicon Pharmaceuticals has a consensus rating of “Hold” and an average target price of $5.80.

Lexicon Pharmaceuticals News Roundup

Here are the key news stories impacting Lexicon Pharmaceuticals this week:

• Positive Sentiment: CEO Michael Exton bought 30,064 shares at an average $1.66, increasing his stake by about 10%. Insider purchases can signal confidence in the company’s prospects. Insider purchase report
• Positive Sentiment: Citigroup raised its price target from $3.10 to $3.40 and maintained a Buy rating, a more optimistic analyst view that may support investor sentiment. Citigroup ratings
• Positive Sentiment: New investigator-led research reported that sotagliflozin reduced thrombus formation in a crossover study and acutely lowered myocardial work in living heart tissue from patients with hypertrophic cardiomyopathy. These findings provide mechanistic evidence for the drug, but do not establish clinical benefit; SONATA-HCM topline results are expected in Q1 2027. Lexicon research announcement
• Neutral Sentiment: A report says short interest totaled zero shares as of November 10, despite describing this as an increase. The conflicting wording makes the figure difficult to interpret as a clear trading signal.
• Neutral Sentiment: Recent analyst views remain mixed: the report cites three Buy ratings, one Hold and one Sell, with an overall consensus Hold. Analyst insights

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals is a biopharmaceutical company based in The Woodlands, Texas. Founded in 1995 as Lexicon Genetics, the company uses drug discovery and development research to create medicines for serious diseases, with a focus on areas of unmet medical need. Its commercial product, Inpefa (sotagliflozin), is approved in the United States to reduce the risk of cardiovascular death and worsening heart failure in adults with heart failure. Lexicon also develops investigational medicines, including candidates studied for neuropathic pain and other conditions.